Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain Estela Moreno-Martínez; Javier de la Serna-Torraba; Vicente Escudero-Vilaplana; José Ángel Hernández-Rivas; Marina Sánchez-Cuervo; Raquel Sánchez-Hernández;

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain José Ramón González-Porras; Francisco Javier Parrondo García; Eduardo Anguita;

[Translated article] High-risk pediatric medications: A listing proposal by interdisciplinary consensus technique Yolanda Hernández Gago; Pedro J. Alcalá Minagorre; Marrodan; Laura Hernández Sabater; María José Cabañas Poy; Cristina Martínez Roca; Jimena Pérez Moreno;